Myricx

Myricx Bio was focused on the development of novel antibody-drug conjugates (ADCs). Myricx developed a novel class of payloads for ADCs based on inhibition of N-Myristoyltransferase (NMT), an enzyme that is key to cancer cell survival. The company was acquired by Novartis (NYSE: NVS) in 2026 for up to $1.5B.